# Synaps Dx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synaps-dx

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.synapsdx.com
- Latest round: Series A (Sep 30, 2021)
- Investors on record: 1

## About

Synaps Dx is a diagnostic company specializing in advanced Alzheimer’s disease diagnostics, offering innovative tools for early and precise detection to enhance patient care.Synaps Dx, founded in 2016, is based in Rockville, US. The company focuses on developing diagnostic solutions for Alzheimer's disease, aiming to provide healthcare professionals with tools that facilitate timely and accurate diagnoses. In October 2021, Synaps Dx successfully raised USD 10 mn in Series A funding, marking it as a vital investment target. The company has completed 2 deals to date, with their latest deal occurring on October 12, 2021. Synaps Dx operates independently without any known subsidiaries or parent companies.Synaps Dx specializes in advanced diagnostics for Alzheimer's disease, focusing on providing precise and early diagnostic tools to enhance patient care. The company’s primary offerings include innovative testing solutions designed to identify biomarkers associated with Alzheimer's, facilitating timely diagnosis and management of the condition. These diagnostic services are tailored to healthcare providers, including neurologists and primary care physicians, aiming to support their clinical decision-making processes. The products are utilized across North America and select regions in Europe, reaching a diverse range of end-users, from healthcare institutions to patients and their families. By delivering actionable insights into Alzheimer's disease, Synaps Dx addresses critical challenges in early detection and treatment, ultimately aiming to improve patient outcomes.Synaps Dx operates through a model that emphasizes partnerships with healthcare providers and institutions, facilitating the integration of their diagnostic solutions into clinical settings. Revenue is generated through direct transactions with these healthcare entities, which may include fee-for-service agreements for diagnostic tests and related services. The company also engages in collaborative efforts with research institutions and pharmaceutical companies, enhancing its service offerings while expanding its customer base. Specific pricing structures for their diagnostic products are established based on the complexity of the tests and the associated clinical value, ensuring that clients receive tailored solutions that meet their needs. By focusing on high-value diagnostic services, Synaps Dx positions itself as a vital partner in the fight against Alzheimer's disease.In the coming years, Synaps Dx plans to scale up production of DISCERN™, its first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of Alzheimer's disease versus other forms of non-Alzheimer's dementias. The company intends to utilize the USD 10 mn raised in Series A funding to meet the increasing market demand for this innovative testing solution. Synaps Dx is also looking to expand its footprint into additional geographic regions beyond North America and Europe, though specific target markets have not been disclosed. The anticipated growth reflects the company’s commitment to advancing its diagnostic capabilities and improving patient outcomes.

## Funding rounds

- Series A, Sep 30, 2021 — Bull & Bear

## Investors

- Bull & Bear (https://capitalatlas.ai/funds/bull-bear) — Series A